Krishna Menon, PhD, VMD, MRCS
Chief Regulatory Officer

Dr. Menon won the Employee of the Year, President's Award at Eli Lilly for 1999. Later, he was the Director of Operations for the ALS Therapy Development Foundation during 2001-2002 (ALS is acute lateral sclerosis, a disease related to Lou Gehrig's Syndrome). He is a Founder and Board Member of KARD Scientific, Cambridge, MA; KARD Inc., Wilmington, MA; as well as KARD Scientific India, Bangalore, India and KARD Medics, Mumbai, India. He is a Director of Biological Supplies, New York, NY. He is a Member of the Scientific Advisory Board of Nexus Pharmaceuticals, Philadelphia, PA and TheraCour Pharma, Inc., West Haven, CT. He is Distinguished Scientist and Scientific Diplomat for GPC-Biotech, Germany. Dr. Menon is a Certified Toxicologist and a Member of the American Association of Toxicology. He holds a VMD from Triniti University, Peru, and MRCS from Royal University of Copenhagen. He is a practicing veterinary surgeon and human physician, licensed in various countries.

Dr. Menon participated in the development of 8 International and 3 US patents, including the one for Alimta. He has been responsible for 7 FDA approved drugs, 3 of which are blockbusters. While at Harvard, he conducted pre-clinical studies on the important anti-HIV drug, AZT. He is well known for his grasp of scientific and regulatory matters in taking a compound from the Chemist's bench to FDA approval. He is regularly invited to lecture across the globe on the drug development process and the regulatory landscape.